ECSP067039A - Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5 - Google Patents

Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5

Info

Publication number
ECSP067039A
ECSP067039A EC2006007039A ECSP067039A ECSP067039A EC SP067039 A ECSP067039 A EC SP067039A EC 2006007039 A EC2006007039 A EC 2006007039A EC SP067039 A ECSP067039 A EC SP067039A EC SP067039 A ECSP067039 A EC SP067039A
Authority
EC
Ecuador
Prior art keywords
etinil
pirazoles
piridin
mglu5
imidazoles
Prior art date
Application number
EC2006007039A
Other languages
English (en)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Sabine Kolczewski
Richard Hugh Phillip Porter
Eric Vieira
Paul Spurr
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/005881 external-priority patent/WO2004108701A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP067039A publication Critical patent/ECSP067039A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a derivados de diazol de la fórmula general en la que A, E, R1, R2 y R3 tienen los significados definidos en las reivindicaciones y en la descripción, a su utilización para la fabricación de medicamentos destinados al tratamiento de enfermedades y a procesos para la obtención de los mismos.
EC2006007039A 2004-06-01 2006-11-28 Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5 ECSP067039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2004/005881 WO2004108701A1 (en) 2003-06-05 2004-06-01 Imidazole derivatives as glutmate receptor antagonists
EP04021216 2004-09-07

Publications (1)

Publication Number Publication Date
ECSP067039A true ECSP067039A (es) 2006-12-29

Family

ID=35758209

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007039A ECSP067039A (es) 2004-06-01 2006-11-28 Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5

Country Status (20)

Country Link
US (2) US20060030559A1 (es)
JP (1) JP4690395B2 (es)
KR (2) KR100907108B1 (es)
AR (1) AR054072A1 (es)
AU (1) AU2005250101B2 (es)
BR (1) BRPI0511678A (es)
CA (1) CA2568725C (es)
CR (1) CR8742A (es)
CY (1) CY1108232T1 (es)
DK (1) DK1756086T3 (es)
EA (1) EA011722B1 (es)
EC (1) ECSP067039A (es)
ES (1) ES2307182T3 (es)
HR (1) HRP20080363T3 (es)
IL (1) IL179524A (es)
MA (1) MA28602B1 (es)
NZ (1) NZ551253A (es)
PT (1) PT1756086E (es)
SI (1) SI1756086T1 (es)
TW (1) TWI297683B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329703B2 (en) * 2005-02-15 2012-12-11 Xtl Biopharmaceuticals Ltd. Pyrazole compounds
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2017117708A1 (en) * 2016-01-05 2017-07-13 Hua Medicine (Shanghai) Ltd. Pyrazole derivatives
MX2018011765A (es) * 2016-03-30 2019-05-20 Sinntaxis AB Moduladores alostéricos negativos del receptor 5 metabotrópico de glutamato (mglur5) para su uso en el tratamiento de daños cerebrales maduros.
IL298709A (en) 2020-06-05 2023-02-01 Noema Pharma Ag Methods for treating multiple sclerosis complex
CN115989024A (zh) * 2020-07-30 2023-04-18 诺埃玛制药公司 治疗三叉神经痛的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3033199A (en) * 1959-10-13 1962-05-08 Jacobs Clifford Roy Closure for protective device
US3045022A (en) 1960-04-07 1962-07-17 Reilly Tar & Chem Corp Process of preparing ethynylpyridines
US3303199A (en) 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) * 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
EP0079312A3 (de) 1981-11-11 1984-04-25 Ciba-Geigy Ag Heterocyclische Acetylenverbindungen
US4711962A (en) * 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
HU217958B (hu) 1989-06-30 2000-05-28 E. I. Du Pont De Nemours And Co. Helyettesített imidazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
CA2297732C (en) 1997-08-14 2008-04-29 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
WO2001016121A1 (en) * 1999-08-31 2001-03-08 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
MXPA02003740A (es) 1999-10-15 2002-09-30 Hoffmann La Roche Derivados de benzodiazepina.
IL136553A0 (en) 2000-06-05 2001-06-14 Compugen Ltd SPLICE VARIANT OF mGluR
JP5154728B2 (ja) 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
ATE288898T1 (de) * 2000-12-04 2005-02-15 Hoffmann La Roche Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
EP1238586A1 (en) 2001-03-09 2002-09-11 Basf Aktiengesellschaft Herbicidal 2-alkynyl-pyri(mi)dines
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
DE60226756D1 (de) 2001-10-04 2008-07-03 Merck & Co Inc Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1458385A4 (en) 2001-12-19 2005-12-21 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
EP1556142A4 (en) 2002-10-24 2006-11-08 Merck & Co Inc ALKYN DERIVATIVES AS TRACERS FOR THE METABOTROPE GLUTAMATE RECEPTOR BINDING
ITMI20030151A1 (it) 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives
US7452909B2 (en) * 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
DE102004032567A1 (de) 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine

Also Published As

Publication number Publication date
JP2008500979A (ja) 2008-01-17
AU2005250101A1 (en) 2005-12-15
US20060030559A1 (en) 2006-02-09
MA28602B1 (fr) 2007-05-02
SI1756086T1 (sl) 2008-08-31
KR101057032B1 (ko) 2011-08-16
TWI297683B (en) 2008-06-11
EA011722B1 (ru) 2009-04-28
CY1108232T1 (el) 2014-02-12
CA2568725C (en) 2012-11-27
AR054072A1 (es) 2007-06-06
EA200602154A1 (ru) 2007-06-29
CA2568725A1 (en) 2005-12-15
AU2005250101B2 (en) 2011-08-25
IL179524A (en) 2012-04-30
NZ551253A (en) 2010-07-30
PT1756086E (pt) 2008-08-08
US20100048569A1 (en) 2010-02-25
HK1105972A1 (zh) 2008-02-29
KR20070021231A (ko) 2007-02-22
TW200609222A (en) 2006-03-16
IL179524A0 (en) 2007-05-15
BRPI0511678A (pt) 2008-01-08
JP4690395B2 (ja) 2011-06-01
KR100907108B1 (ko) 2009-07-09
DK1756086T3 (da) 2008-08-04
CR8742A (es) 2007-08-28
ES2307182T3 (es) 2008-11-16
US8293916B2 (en) 2012-10-23
KR20080089523A (ko) 2008-10-06
HRP20080363T3 (hr) 2008-09-30

Similar Documents

Publication Publication Date Title
CR20120332A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos.
CR10233A (es) Piridin-4-ilmetilamidas
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
PE20151788A1 (es) Inhibidores de bromodominios tetraciclicos
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
CR11429A (es) Derivados bis-(sulfonilamino) en terapia 066
PA8647401A1 (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa,
CU20120013A7 (es) Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
MX381849B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
CO6541656A2 (es) 2-amino-5.5- difluor-5.6-dihidro-4h-oxazinas como inhibidores de bace1 y/o bace 2
ECSP13012967A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
BR112014005468A2 (pt) derivados de aminopiridina para uso como moduladores de atividade quinase
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
SV2011003855A (es) Heteroarilos sustituidos
UY30328A1 (es) Derivados de 2-piridona, procesos de preparacion, composiciones conteniéndolos y aplicaciones.
UY32918A (es) Nuevos compuestos de 2-piridona
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
UY31016A1 (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38